PMID- 34620002
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230403
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 36
IP  - 2
DP  - 2023 Apr
TI  - Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the 
      Glucagon-Like Peptide-1 (GLP-1) Pipeline?
PG  - 418-428
LID - 10.1177/08971900211049032 [doi]
AB  - Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose 
      levels, suppress glucagon secretion, and slow gastric emptying. These properties 
      make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are 
      many FDA-approved GLP-1 agonists on the market today, several of which have 
      demonstrated benefit beyond improving glycemic control. Given the beneficial 
      effects of GLP-1 agonists in patients with T2DM, new drugs are in development 
      that combine the mechanism of action of GLP-1 receptor agonism with novel 
      mechanisms and with drugs that promote GLP-1 secretion. These agents are designed 
      to improve glycemic control and target greater body weight reduction. This 
      article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.
FAU - Elder, Mary J
AU  - Elder MJ
AUID- ORCID: 0000-0001-8061-0201
AD  - Pharmacy Innovations and Partnerships, 21614Michigan Medicine, Ann Arbor, MI, 
      USA.
FAU - Ashjian, Emily J
AU  - Ashjian EJ
AUID- ORCID: 0000-0001-5746-0233
AD  - Department of Clinical Pharmacy, 15514University of Michigan College of Pharmacy, 
      Ann Arbor, MI, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211007
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide 1/pharmacology/therapeutic use
MH  - Hypoglycemic Agents/adverse effects
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Body Weight
OTO - NOTNLM
OT  - G protein-coupled receptor 119 agonist
OT  - diabetes mellitus
OT  - gastric inhibitory polypeptide
OT  - glucagon receptor agonist
OT  - glucagon-like peptide-1 receptor agonist
EDAT- 2021/10/09 06:00
MHDA- 2023/04/03 06:41
CRDT- 2021/10/08 05:34
PHST- 2023/04/03 06:41 [medline]
PHST- 2021/10/09 06:00 [pubmed]
PHST- 2021/10/08 05:34 [entrez]
AID - 10.1177/08971900211049032 [doi]
PST - ppublish
SO  - J Pharm Pract. 2023 Apr;36(2):418-428. doi: 10.1177/08971900211049032. Epub 2021 
      Oct 7.